Alphatec (NASDAQ:ATEC) EVP David Sponsel Sells 60,425 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 60,425 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $13.79, for a total value of $833,260.75. Following the completion of the sale, the executive vice president directly owned 349,500 shares of the company’s stock, valued at $4,819,605. The trade was a 14.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

David Sponsel also recently made the following trade(s):

• On Wednesday, December 10th, David Sponsel sold 21,106 shares of Alphatec stock. The stock was sold at an average price of $20.79, for a total transaction of $438,793.74.
• On Monday, December 8th, David Sponsel sold 988 shares of Alphatec stock. The shares were sold at an average price of $21.45, for a total value of $21,192.60.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $13.82 on Friday. The firm has a fifty day moving average of $18.85 and a 200 day moving average of $17.01. Alphatec Holdings, Inc. has a one year low of $8.81 and a one year high of $23.29. The firm has a market cap of $2.05 billion, a PE ratio of -13.29 and a beta of 1.01. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ATEC. TD Cowen reaffirmed a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Morgan Stanley set a $23.00 price objective on Alphatec in a research note on Tuesday, December 2nd. Canaccord Genuity Group lifted their price objective on Alphatec from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Stifel Nicolaus started coverage on shares of Alphatec in a research report on Tuesday, October 28th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Alphatec in a report on Monday, January 12th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.82.

Institutional Trading of Alphatec

Several large investors have recently added to or reduced their stakes in the business. Creative Planning increased its position in shares of Alphatec by 0.9% during the 3rd quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock valued at $853,000 after purchasing an additional 534 shares during the period. Valeo Financial Advisors LLC grew its stake in shares of Alphatec by 2.1% in the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock worth $600,000 after purchasing an additional 846 shares during the last quarter. Norden Group LLC raised its holdings in shares of Alphatec by 2.6% in the 3rd quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock worth $533,000 after purchasing an additional 939 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Alphatec by 2.8% in the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after buying an additional 949 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Alphatec by 8.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock worth $131,000 after acquiring an additional 955 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.